ATRA:NSD-Atara Biotherapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 23.27

Change

+0.28 (+1.22)%

Market Cap

USD 1.79B

Volume

0.37M

Average Target Price

USD 28.00 (+20.33%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms Tumor 1; and ATA621 for BK and JCV. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+8.61 (+3.95%)

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+5.74 (+1.13%)

USD54.24B 20.76 16.02
MRNA Moderna, Inc

+17.85 (+16.35%)

USD43.20B N/A N/A
SGEN Seagen Inc

+3.67 (+2.22%)

USD29.62B 62.48 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.90 (+0.73%)

USD26.90B 28.53 26.40
RPRX Royalty Pharma plc

+0.63 (+1.54%)

USD25.62B 22.60 9.61
BNTX BioNTech SE

+5.03 (+4.79%)

USD25.27B -99,999.99 N/A
GMAB Genmab A/S

+1.22 (+3.40%)

USD23.59B 26.59 2.65
BGNE BeiGene, Ltd

+21.73 (+8.23%)

USD23.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ATRA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 41.29% 68% D+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.29% 68% D+ 77% C+
Trailing 12 Months  
Capital Gain 63.76% 70% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.76% 70% C- 81% B-
Trailing 5 Years  
Capital Gain -41.19% 46% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.19% 46% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain 13.89% N/A N/A 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.89% N/A N/A 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 88.37% N/A N/A 10% F
Risk Adjusted Return 15.72% N/A N/A 43% F
Market Capitalization 1.79B 83% B 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.09 41% F 27% F
Price / Cash Flow Ratio -7.58 55% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -90.37% 34% F 13% F
Return on Invested Capital -93.92% 29% F 10% F
Return on Assets -49.83% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 18.47 7% F 3% F
Short Percent 20.39% 10% F 10% F
Beta 2.29 15% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector